Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Aspen to Dispatch 300 000 J&J Vaccines for Teachers

06/15/2021 | 11:06am EDT

Aspen says it will release 300 000 Johnson & Johnson (J&J) doses earmarked for teachers soon.

In a statement released on Monday, Aspen said it was "extremely disappointed" to learn that specific batches of the J&J manufactured at its Gqeberha production site have to be destroyed.

This is due to the good manufacturing practice risk of isolated material in the drug substance supplied to Aspen by J&J from their contract-manufacturing partner in the United States.

"The batches manufactured had been retained in storage awaiting the outcome of the US FDA assessment," Aspen said.

On Sunday, the South African Health Products Regulatory Authority (SAHPRA) said it decided not to release the long-awaited Johnson & Johnson (J&J) vaccines for use in the country.

However, SAHPRA said about 300 000 doses from batches that have been cleared by the US Food & Drug Administration (FDA) meet the requirements and will subsequently be released and shipped to South Africa.

According to the pharmaceutical company, this is not only a setback to both the Aspen and J&J teams, who worked tirelessly to produced these shots, but it has the potential to negatively affect vaccine rollout across South Africa and Africa.

However, the company has since come out with ways to mitigate the potential risk to vaccine access.

"Within days, Johnson & Johnson will provide 300 000 doses of the vaccine for South African teachers," the company announced.

In the next week, Aspen said it expects to release J&J vaccines manufactured from the drug substance that has not been impacted by the contamination.

"Over the next few weeks, Johnson & Johnson will be delivering substantial quantities of compliant, finished vaccines to South Africa to replace the lost stock, thereby ensuring the momentum in the South African vaccine initiative is maintained."

The multinational said further doses of the lifesaving vaccines will become available in July.

"These Johnson & Johnson vaccines released by Aspen will support the vaccination programmes in South Africa and elsewhere in Africa."

Aspen has thanked its team and J&J for its exemplary response in managing this setback.

"Through their actions, they have not only assisted in capacitating the African continent but at this challenging time, they have stepped up again to ensure that we are able to maintain the momentum needed to give our continent access to lifesaving vaccines."

Copyright SAnews.gov.za. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

All news about JOHNSON & JOHNSON
10:36aJOHNSON & JOHNSON : FDA - Coronavirus Update
05:06aJOHNSON & JOHNSON : U.S. Govt Donates 151,200 Doses of J&J Vaccines to MoH
05:06aJOHNSON & JOHNSON : 11,000 Tunisian Students Studying Abroad to Receive Covid-19..
08/03ZYMEWORKS : Says Earned Milestone Payment From Johnson & Johnson Under Licensing..
08/03Johnson & Johnson Appoints Sandipan Ghatak as Head of Consumer Health India C..
08/03CORONAVIRUS : AVAT to partner with UNICEF in scaling up vaccine deliveries to Af..
08/03CORONAVIRUS : AVAT to partner with UNICEF in scaling up vaccine deliveries to Af..
08/03JOHNSON & JOHNSON : Eyes Ways To Fast-Track COVID-19 Vaccine Delivery To India
08/02JOHNSON & JOHNSON : Janssen Pharmaceutical - UPTRAVI Receives FDA Approval for I..
08/02MARKET CHATTER : Johnson & Johnson Reportedly in Ongoing Talks With India on COV..
More news
Financials (USD)
Sales 2021 94 457 M - -
Net income 2021 22 808 M - -
Net Debt 2021 853 M - -
P/E ratio 2021 20,3x
Yield 2021 2,40%
Capitalization 456 B 456 B -
EV / Sales 2021 4,84x
EV / Sales 2022 4,62x
Nbr of Employees 134 500
Free-Float 84,3%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 173,36 $
Average target price 184,35 $
Spread / Average Target 6,34%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON10.81%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.24.10%255 703
NOVARTIS AG-0.20%224 638
NOVO NORDISK A/S36.67%213 138